A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 May 2018
At a glance
- Drugs Amrubicin (Primary)
- Indications Malignant thymoma; Thymoma
- Focus Therapeutic Use
- 17 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 12 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 20 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History